This study tests a new treatment for non-small cell lung cancer (NSCLC) that has spread or come back after treatment. It combines three medicines: Pembrolizumab (helps the immune system fight cancer), Ramucirumab (stops new blood vessels from growing), and Docetaxel (prevents cancer cells from dividing). Patients will receive these medicines through an IV (a needle in the vein) every 21 days. The study will continue until the cancer worsens, severe side effects occur, or the patient decides to stop.

Key points to consider:

• The study includes regular visits every 21 days and follow-up calls for up to 10 years.
• Participants should not have had prior treatments with Docetaxel or Ramucirumab.
• There are risks of side effects from the combination of drugs being used in this study.

Participants must have NSCLC and have tried other treatments that didn't work. They should not be pregnant or breastfeeding, and both men and women need to use birth control during the study. They must also meet certain health criteria, like having a certain level of blood cells and organ function.